WASHINGTON – Sustained virologic response rates for genotype 1 and 2 patients are lower with sofosbuvir-based hepatitis C virus regimens in routine clinical practice than clinical trials, results...
In a report published in Hepatology, scientists from the FDA’s Division of Antiviral Products in the Center for Drug Evaluation and Research (CDER) have provided a brief overview of the FDA’s...
WASHNGTON – An experimental acid suppressant was effective for prevention of peptic ulcer recurrence during NSAID therapy, with a safety profile similar to that of a currently marketed proton-pump...
Patients with Crohn’s disease could benefit from a “treat-to-target” approach based on intervening early to reverse inflammation and gathering objective data to guide clinical decisions, according to...
Even high-volume referral centers varied significantly in their use of immunomodulators and some other therapies for patients with inflammatory bowel disease, particularly Crohn’s disease, a...
Among patients with single-nodule hepatocellular carcinomas diagnosed by computed tomography, further imaging with gadoxetic acid–enhanced magnetic resonance (MR) revealed more tumors and was tied to...
In adults with inflammatory bowel disease (IBD), basing maintenance infliximab dosing on serum trough concentrations instead of clinical response led to significantly fewer flares and cut costs by...
WASHINGTON – The anti-MAdCAM candidate, PF-00547659, induced responses in up to 54% of patients with moderately to severely active ulcerative colitis failing at least one prior therapy.
At the...
WASHINGTON – Even wonder drugs have their limits: Aspirin use was associated with a significant reduction in the incidence of noncardiac gastric adenocarcinoma, but it had no effect on the incidence...
The Food and Drug Administration has approved Viberzi (eluxadoline) and Xifaxan (rifaximin) to treat irritable bowel syndrome with diarrhea (IBS-D) in adults, the agency announced May 27.
Viberzi is...